Novel multi‐peptide vaccination in Hla‐A2+ hormone sensitive patients with biochemical relapse of prostate cancer
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
BACKGROUND: A phase I/II trial was conducted to assess feasibility and tolerability of tumor associated antigen peptide vaccination in hormone sensitive prostate carcinoma (PC) patients with biochemical recurrence after primary surgical treatment. METHODS: Nineteen HLA‐A2 positive patients with rising PSA without detectable metastatic disease or local recurrence received 11 HLA‐A*0201‐restricted and two HLA class II synthetic peptides derived from PC tumor antigens subcutaneously for 18 months or until PSA progression. The vaccine was emulgated in montanide ISA51 and combined with imiquimod, GM‐CSF, mucin‐1‐mRNA/protamine complex, local hyperthermia or no adjuvant. PSA was assessed, geometric mean doubling times (DT) calculated and clinical performance monitored. RESULTS: PSA DT of 4 out of 19 patients (21%) increased from 4.9 to 25.8 months during vaccination. Out of these, two patients (11%) exhibited PSA stability for 28 and 31 months which were still continuing at data cut‐off. One patient showed no change of PSA DT during vaccination but decline after the therapy. Three patients had an interim PSA decline or DT increase followed by DT decrease compared to baseline PSA DT. Three of the responding patients received imiquimod and one the mucin‐1‐mRNA/protamine complex as adjuvant; both are Toll‐like receptor‐7 agonists. Eleven (58%) patients had progressive PSA values. The vaccine was well tolerated, and no grade III or IV toxicity occurred. CONCLUSION: Multi‐peptide vaccination stabilized or slowed down PSA progress in four of 19 cases. The vaccination approach is promising with moderate adverse events. Long‐term stability delayed androgen deprivation up to 31 months. TLR‐7 co‐activation seems to be beneficial. Prostate 69: 917–927, 2009. © 2009 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Tiwari, R. C., Murray, T., Ghafoor, A., Samuels, A., Ward, E., Feuer, E. J., & Thun, M. J. (2004) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.54.1.8 · Cited by 3,984
Cited by
Therapeutic vaccines for cancer: an overview of clinical trials
Melero, I., Gaudernack, G., Gerritsen, W., Huber, C., Parmiani, G., Scholl, S., Thatcher, N., Wagstaff, J., Zielinski, C., Faulkner, I., et al. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.111 · Cited by 776
Steinhagen, F., Kinjo, T., Bode, C., & Klinman, D. M. (2011) · Vaccine · doi:10.1016/j.vaccine.2010.08.002 · Cited by 501
mRNA vaccine: a potential therapeutic strategy
Wang, Y., Zhang, Z., Luo, J., Han, X., Wei, Y., & Wei, X. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01311-z · Cited by 422
Unmet needs in modern vaccinology
Leroux-Roels, G. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.07.021 · Cited by 304
A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity
Heitmann, J. S., Bilich, T., Tandler, C., Nelde, A., Maringer, Y., Marconato, M., Reusch, J., Jäger, S., Denk, M., Richter, M., et al. (2022) · Nature · doi:10.1038/s41586-021-04232-5 · Cited by 255
Self-citationThe Peptide Vaccine of the Future
Nelde, A., Rammensee, H.-G., & Walz, J. S. (2021) · Molecular & Cellular Proteomics · doi:10.1074/mcp.r120.002309 · Cited by 205
“In the phase I to III clinical trials of the offthe-shelf multipeptide vaccine IMA901 for the treatment of renal cell carcinoma with a total of 302 vaccinated patients (70, 134) as well as in the phase I/II trial of an antiprostate cancer vaccine treating 19 patients (152) no evidence of autoimmunity was observed.”
BackgroundSelf-citationNext-generation peptide vaccines for advanced cancer
Yamada, A., Sasada, T., Noguchi, M., & Itoh, K. (2013) · Cancer Science · doi:10.1111/cas.12050 · Cited by 124
Peptide-based vaccine for cancer therapies
Buonaguro, L., & Tagliamonte, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1210044 · Cited by 110
Widenmeyer, M., Griesemann, H., Stevanović, S., Feyerabend, S., Klein, R., Attig, S., Hennenlotter, J., Wernet, D., Kuprash, D. V., Sazykin, A. Y., et al. (2012) · International Journal of Cancer · doi:10.1002/ijc.26365 · Cited by 70
“The study analysis is still ongoing and details of the design, conditions and vaccination schedule can be found in an interim report recently published.(27) Briefly, the vaccination cocktail consists of 14 synthetic peptides, 12 HLAA*0201 restricted T cell epitopes derived from prostate TAA or from the Influenza matri…”
MethodSelf-citation
Metadata
- Authors
- Feyerabend, S., Stevanovic, S., Gouttefangeas, C., Wernet, D., Hennenlotter, J., Bedke, J., Dietz, K., Pascolo, S., Kuczyk, M., Rammensee, H., & Stenzl, A.
- Venue
- The Prostate
- Publisher
- Wiley
- Published
- 2009-03-06
- Volume
- 69
- Issue
- 9
- Pages
- 917-927
- ISSN
- 0270-4137 (ISSN-L)
- 1097-0045
- OpenAlex
- W2043461098
- Cited by
- 107
- References
- 1
- FWCI
- 3.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.